JP Morgan Chase
BDTX icon

JP Morgan Chase’s Black Diamond Therapeutics BDTX Stock Holding History

JP Morgan Chase’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,000
Closed -$60.9K – 7396
2024
Q3 		$60.9K Buy
+14,000
New +$76.2K ﹤0.01% 5919

Other funds holding BDTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

JP Morgan Chase's BDTX Position: Q2 2026 in Review

JP Morgan Chase increased its Black Diamond Therapeutics (BDTX) stake by 530% in Q2 2026, buying an estimated $60.2K and bringing the position to 29,242 shares worth $51.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6412.

JP Morgan Chase first reported a position in BDTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $11.5M in Q4 2020. 55 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • JP Morgan Chase held 29,242 shares of Black Diamond Therapeutics worth $51.2K as of Q2 2026.
  • JP Morgan Chase bought 24,604 Black Diamond Therapeutics shares in Q2 2026, an estimated $60.2K.
  • Black Diamond Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6412 holding.
  • JP Morgan Chase first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Black Diamond Therapeutics position peaked at $11.5M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.